Organon Posts Strong Q3 2024 Financial Results
Company Announcements

Organon Posts Strong Q3 2024 Financial Results

The latest update is out from Organon ( (OGN) ).

Organon reported robust financial results for Q3 2024, with a revenue increase to $1.582 billion, driven by strong performances in Women’s Health and Biosimilars. Nexplanon and Hadlima fueled growth, despite challenges from generic competition and pricing pressures. The company also narrowed its full-year revenue guidance, reflecting confidence in its strategic execution. Earnings per share rose significantly, benefiting from a tax asset valuation adjustment, highlighting Organon’s disciplined cost management and growth strategy.

Learn more about OGN stock on TipRanks’ Stock Analysis page.

Related Articles
TheFlyOrganon reports FDA extension of target action date of review of Vtama sNDA
TipRanks Auto-Generated NewsdeskOrganon’s VTAMA Cream FDA Review Extended to 2025
TipRanks Auto-Generated NewsdeskOrganon & Co. Reports Strong Third Quarter 2024 Results
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App